nach oben

Die Gastroenterologie

Erschienen in:

11.06.2021 | Chronisch-entzündliche Darmerkrankungen | CME

Überwachung und Management von Dysplasien bei chronisch-entzündlichen Darmerkrankungen

verfasst von: PD Dr. med. Elisabeth Schnoy, Helmut Messmann, Ralf Kiesslich

Erschienen in: Die Gastroenterologie | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Patienten mit chronisch-entzündlichen Darmerkrankungen (CED) haben ein erhöhtes Risiko für die Entwicklung von Kolonkarzinomen. Risikofaktoren sind unter anderem die chronisch-persistierende Entzündungsaktivität und bei der Colitis ulcerosa die Krankheitsausdehnung. Die frühzeitige Detektion von Dysplasien und Frühmalignomen ist durch die Etablierung von entsprechenden hochqualitativen Vorsorgeendoskopien, z. B. mit Chromendoskopie, möglich geworden. Durch eine rechtzeitige risikoadaptierte endoskopische Überwachung kann die Prognose der Patienten deutlich verbessert werden.

Petritsch W, Fuchs S, Berghold A, Bachmaier G, Hogenauer C, Hauer AC, Weiglhofer U, Wenzl HH (2013) Incidence of inflammatory bowel disease in the province of Styria, Austria, from 1997 to 2007: a population-based study. J Crohns Colitis 7:58–69PubMed

Lucendo AJ, Hervias D, Roncero O, Lorente R, Bouhmidi A, Angueira T, Verdejo C, Saluena I, Gonzalez-Castillo S, Arias A (2014) Epidemiology and temporal trends (2000-2012) of inflammatory bowel disease in adult patients in a central region of Spain. Eur J Gastroenterol Hepatol 26:1399–1407PubMed

Ott C, Obermeier F, Thieler S, Kemptner D, Bauer A, Scholmerich J, Rogler G, Timmer A (2008) The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. Eur J Gastroenterol Hepatol 20:917–923PubMed

Lophaven SN, Lynge E, Burisch J (2017) The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study. Aliment Pharmacol Ther 45:961–972PubMed

Crohn BB, Ginzburg L, Oppenheimer GD (2000) Regional ileitis: a pathologic and clinical entity. 1932. Mt Sinai J Med 67:263–268PubMed

Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337:1029–1035PubMed

Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65PubMed

Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, Lasch K (2018) Efficacy of vedolizumab in Fistulising Crohn’s disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis 12:621–626PubMedPubMedCentral

Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van AG, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369:699–710PubMed

10.

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr., Dieleman LA, Katz S, Rutgeerts P (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375:1946–1960PubMed

11.

Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panes J (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376:1723–1736PubMed

12.

Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van AG, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381:1201–1214PubMed

13.

Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D’Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr., Marteau P, Munkholm P, Murdoch TB, Ordas I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van AG, Danese S, Panes J, Bouguen G, O’Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF (2015) Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110:1324–1338PubMed

14.

Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Scholmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A (2021) STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160(5):1570–1583. https://doi.org/10.1053/j.gastro.2020.12.031CrossRefPubMed

15.

Dal BA, Roda G, Argollo M, Peyrin-Biroulet L, Danese S (2020) Histological healing: should it be considered as a new outcome for ulcerative colitis? Expert Opin Biol Ther 20:407–412

16.

Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, Duclos B, Bourreille A, Faivre J, Peyrin-Biroulet L, Flejou JF, Carrat F (2013) Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 145:166–175PubMed

17.

Jess T, Winther KV, Munkholm P, Langholz E, Binder V (2004) Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 19:287–293PubMed

18.

Winther KV, Jess T, Langholz E, Munkholm P, Binder V (2004) Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2:1088–1095PubMed

19.

Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T (2010) Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 105:1480–1487PubMed

20.

Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R (2015) European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis 9:945–965PubMed

21.

Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A (2001) Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet 357:262–266PubMed

22.

Baars JE, Looman CW, Steyerberg EW, Beukers R, Tan AC, Weusten BL, Kuipers EJ, van der Woude CJ (2011) The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 106:319–328PubMed

23.

Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816PubMed

24.

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558PubMedPubMedCentral

25.

Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7–G17PubMed

26.

Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS (1992) DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103:1611–1620PubMed

27.

Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, Hontanosas M, Newkirk C, Meltzer SJ (1993) p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 104:1633–1639PubMed

28.

Pereira C, Coelho R, Gracio D, Dias C, Silva M, Peixoto A, Lopes P, Costa C, Teixeira JP, Macedo G, Magro F (2016) DNA damage and oxidative DNA damage in inflammatory bowel disease. J Crohns Colitis 10:1316–1323PubMed

29.

Kewenter J, Ahlman H, Hulten L (1978) Cancer risk in extensive ulcerative colitis. Ann Surg 188:824–828PubMedPubMedCentral

30.

Gyde SN, Prior P, Macartney JC, Thompson H, Waterhouse JA, Allan RN (1980) Malignancy in Crohn’s disease. Gut 21:1024–1029PubMedPubMedCentral

31.

Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B (2013) Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 19:789–799PubMed

32.

Jess T, Loftus EV Jr., Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Tremaine WJ, Melton LJ III, Munkholm P, Sandborn WJ (2006) Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis 12:669–676PubMed

33.

Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M (2012) Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 143:375–381PubMed

34.

Jess T, Rungoe C, Peyrin-Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10:639–645PubMed

35.

Castano-Milla C, Chaparro M, Gisbert JP (2014) Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 39:645–659PubMed

36.

Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de AM, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagorowicz E, Raine T, Harbord M, Rieder F (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders. J Crohns Colitis 11:649–670PubMed

37.

Wijnands AM, de Jong ME, Lutgens MWMD, Hoentjen F, Elias SG, Oldenburg B (2020) Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis. Gastroenterology 160(5):1584–1598. https://doi.org/10.1053/j.gastro.2020.12.036CrossRefPubMed

38.

Manninen P, Karvonen AL, Huhtala H, Aitola P, Hyoty M, Nieminen I, Hemminki H, Collin P (2013) The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20 years. J Crohns Colitis 7:e551–e557PubMed

39.

Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A (2004) Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53:1813–1816PubMedPubMedCentral

40.

Velayos FS, Loftus EV Jr., Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ (2006) Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 130:1941–1949PubMed

41.

Mahmoud R, Shah SC, Ten Hove JR, Torres J, Mooiweer E, Castaneda D, Glass J, Elman J, Kumar A, Axelrad J, Ullman T, Colombel JF, Oldenburg B, Itzkowitz SH (2019) No association between pseudopolyps and colorectal neoplasia in patients with inflammatory bowel diseases. Gastroenterology 156:1333–1344PubMed

42.

Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J, Turner JR (2013) Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 11:1601–1608PubMed

43.

Mahmoud R, Shah SC, Torres J, Castaneda D, Glass J, Elman J, Kumar A, Axelrad J, Harpaz N, Ullman T, Colombel JF, Oldenburg B, Itzkowitz SH (2020) Association between indefinite dysplasia and advanced neoplasia in patients with inflammatory bowel diseases undergoing surveillance. Clin Gastroenterol Hepatol 18:1518–1527PubMed

44.

Sonnenberg A, Genta RM (2015) Epithelial dysplasia and cancer in IBD strictures. J Crohns Colitis 9:769–775PubMed

45.

Lee HS, Park SH, Yang SK, Ye BD, Kim JH, Kim SO, Soh JS, Lee S, Bae JH, Lee HJ, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH (2015) The risk of colorectal cancer in inflammatory bowel disease: a hospital-based cohort study from Korea. Scand J Gastroenterol 50:188–196PubMed

46.

Beaugerie L, Carrat F, Nahon S, Zeitoun JD, Sabate JM, Peyrin-Biroulet L, Colombel JF, Allez M, Flejou JF, Kirchgesner J, Svrcek M (2018) High risk of anal and rectal cancer in patients with anal and/or Perianal Crohn’s disease. Clin Gastroenterol Hepatol 16:892–899PubMed

47.

Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, Kowdley KV, Stevens AC, Crispin DA, Emond M, Rubin CE (1996) Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 110:331–338PubMed

48.

D’Haens GR, Lashner BA, Hanauer SB (1993) Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 88:1174–1178PubMed

49.

Claessen MM, Lutgens MW, van Buuren HR, Oldenburg B, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Siersema PD, Vleggaar FP (2009) More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 15:1331–1336PubMed

50.

Unal NG, Ozutemiz O, Tekin F, Turan I, Osmanoglu N (2019) Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. Turk J Gastroenterol 30:139–147PubMed

51.

Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM (1998) Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 115:1079–1083PubMed

52.

Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R (2015) SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc 81:489–501PubMed

53.

German Society for Digestive and Metabolic Diseases (DGVS) (2019) Updated S3-guideline ulcerative colitis. Z Gastroenterol 57:162–241

54.

Hlavaty T, Huorka M, Koller T, Zita P, Kresanova E, Rychly B, Toth J (2011) Colorectal cancer screening in patients with ulcerative and Crohn’s colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. Eur J Gastroenterol Hepatol 23:680–689PubMed

55.

Murthy S, Goetz M, Hoffman A, Kiesslich R (2012) Novel colonoscopic imaging. Clin Gastroenterol Hepatol 10:984–987PubMed

56.

Buchner AM, Shahid MW, Heckman MG, McNeil RB, Cleveland P, Gill KR, Schore A, Ghabril M, Raimondo M, Gross SA, Wallace MB (2010) High-definition colonoscopy detects colorectal polyps at a higher rate than standard white-light colonoscopy. Clin Gastroenterol Hepatol 8:364–370PubMed

57.

Brooker JC, Saunders BP, Shah SG, Thapar CJ, Thomas HJ, Atkin WS, Cardwell CR, Williams CB (2002) Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial. Gastrointest Endosc 56:333–338PubMed

58.

Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, Nafe B, Jung M, Galle PR, Neurath MF (2003) Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124:880–888PubMed

59.

Kiesslich R, Neurath MF (2004) Chromoendoscopy: an evolving standard in surveillance for ulcerative colitis. Inflamm Bowel Dis 10:695–696PubMed

60.

Kiesslich R, Neurath MF (2004) Surveillance colonoscopy in ulcerative colitis: magnifying chromoendoscopy in the spotlight. Gut 53:165–167PubMedPubMedCentral

61.

Kiesslich R, Neurath MF (2015) Advances in detection and management of dysplasia in inflammatory bowel disease: Is endoscopic submucosal dissection ready for prime time in inflammatory bowel disease? Gastrointest Endosc 82:739–741PubMed

62.

Carballal S, Maisterra S, Lopez-Serrano A, Gimeno-Garcia AZ, Vera MI, Marin-Garbriel JC, Diaz-Tasende J, Marquez L, Alvarez MA, Hernandez L, De CL, Gordillo J, Puig I, Vega P, Bustamante-Balen M, Acevedo J, Penas B, Lopez-Ceron M, Ricart E, Cuatrecasas M, Jimeno M, Pellise M (2018) Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. Gut 67:70–78PubMed

63.

Kandiah K, Subramaniam S, Thayalasekaran S, Chedgy FJ, Longcroft-Wheaton G, Fogg C, Brown JF, Smith SC, Iacucci M, Bhandari P (2020) Multicentre randomised controlled trial on virtual chromoendoscopy in the detection of neoplasia during colitis surveillance high-definition colonoscopy (the VIRTUOSO trial). Gut. https://doi.org/10.1136/gutjnl-2020-320980CrossRefPubMed

64.

Clarke K, Kang M, Gorrepati VS, Stine JG, Tinsley A, Williams E, Moyer M, Coates M (2020) Dysplasia detection is similar between chromoendoscopy and high-definition white-light colonoscopy in inflammatory bowel disease patients: a US-matched case-control study. Int J Colorectal Dis 35:2301–2307PubMed

65.

Westwood DA, Alexakis N, Connor SJ (2012) Transparent cap-assisted colonoscopy versus standard adult colonoscopy: a systematic review and meta-analysis. Dis Colon Rectum 55:218–225PubMed

66.

Gasia MF, Ghosh S, Panaccione R, Ferraz JG, Kaplan GG, Leung Y, Novak KL, Seow CH, Iacucci M (2016) Targeted biopsies identify larger proportions of patients with colonic neoplasia undergoing high-definition colonoscopy, dye chromoendoscopy, or electronic virtual chromoendoscopy. Clin Gastroenterol Hepatol 14:704–712PubMed

67.

Watanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo SE, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, Hibi T (2016) Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology 151:1122–1130PubMed

68.

Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, Chapman M, Itzkowitz S, Steinlauf AF, Abreu MT, Ullman TA, Aisenberg J, Mayer L (2008) Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol 103:2342–2349PubMed

69.

Kiesslich R, Neurath MF (2017) Advanced endoscopy imaging in inflammatory bowel diseases. Gastrointest Endosc 85:496–508PubMed

70.

Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Gotz M, Katsanos KH, Kiesslich R, Ordas I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R (2013) European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 7:982–1018PubMed

71.

Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO (1994) Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 107:117–120PubMed

72.

Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT (2007) 5‑Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 13:367–371PubMed

73.

Lyakhovich A, Gasche C (2010) Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 31:202–209PubMed

74.

Stolfi C, Pallone F, Monteleone G (2012) Colorectal cancer chemoprevention by mesalazine and its derivatives. J Biomed Biotechnol 2012:980458PubMedPubMedCentral

Titel: Überwachung und Management von Dysplasien bei chronisch-entzündlichen Darmerkrankungen
verfasst von: PD Dr. med. Elisabeth Schnoy
Helmut Messmann
Ralf Kiesslich
Publikationsdatum: 11.06.2021
Verlag: Springer Medizin
Schlagwörter: Chronisch-entzündliche Darmerkrankungen
Colitis ulcerosa
Morbus Crohn
Kolonkarzinom
Kolonkarzinom
Endoskopie
Erschienen in: Die Gastroenterologie / Ausgabe 4/2021
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI: https://doi.org/10.1007/s11377-021-00536-0

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Mitteilungen des BDI

Mitteilungen der Stiftung LebensBlicke

Mitteilungen des Netzwerks gegen Darmkrebs

Submuköse Läsion im Sigma – ein (un)auffälliger Befund?

Prädiktive Biomarker in der immunonkologischen Therapie gastrointestinaler Tumoren: derzeitiger Standard und zukünftige Perspektiven

Tumorvakzinierung –Strategien und Timing

Magen-Darm-Erkrankungen in der Hausarztpraxis